Katalin Karikó

Katalin "Kati" Karikó (born 17 January 1955) is a Hungarian biochemist who specializes in ribonucleic acid (RNA)-mediated mechanisms, particularly in vitro-transcribed messenger RNA (mRNA) for protein replacement therapy. Karikó laid the scientific groundwork for mRNA vaccines, overcoming major obstacles and skepticism in the scientific community. Karikó received the Nobel Prize in Physiology or Medicine in 2023 for her work, along with American immunologist Drew Weissman.

Karikó co-founded and was CEO of RNARx from 2006 to 2013. From 2013 to 2022, she was associated with BioNTech RNA Pharmaceuticals, first as a vice president and promoted to senior vice president in 2019. In 2022, she left BioNTech to devote more time to research. In 2021, she received an honorary doctorate from the University of Szeged in Hungary, where she has since become a professor. While Karikó has also been associated with the University of Pennsylvania, which would benefit financially from her eventual discovery, the university had actively discouraged her from pursuing research by underfunding and deprioritizing work on mRNA. After being demoted by the University of Pennsylvania in 1995, Karikó was never granted tenure and joined BioNTech in 2013 after the university had declined to reinstate her.